PMID- 22097714
OWN - NLM
STAT- MEDLINE
DCOM- 20130221
LR  - 20161125
IS  - 1000-6834 (Print)
IS  - 1000-6834 (Linking)
VI  - 27
IP  - 3
DP  - 2011 Aug
TI  - [Effect of neotype carbonic anhydrase target-based inhibitors(P-8) on the hypoxic 
      tolerance in mice].
PG  - 276-9
AB  - OBJECTIVE: To explore the effects of different doses of P-8 in increasing the 
      Hypoxia tolerance of mice and the mechanisms involved. METHODS: The health mice 
      were placed into the oxygen deficit bottles and measured the survival time in the 
      condition of hypoxia. The male mice were put into the ladder cage, then placed 
      them into the hypobaric champer to determine the survival time of mice with 
      decompression hypoxia (min). We observed the activity changes of the mice's 
      organization carbonic anhydrase II (CAII). By using the drug in prophylaxis, we 
      investigated the effects of carbonic anhydrase target-based inhibitors P-8 for 
      improving the hypoxia tolerance. RESULTS: (1) In improving the endurance of mice 
      in the condition of hypoxia, the survival time of 6.25 mg/(kg x d) and more doses 
      of P-8 groups were (27.38 +/- 4.63, 29.53 +/- 4.43, 29.67 +/- 7.28, 31.55 +/- 
      6.34, 32.45 +/- 6.65, 36.81 +/- 7.24 and 35.41 +/- 4.20) min, compared with the 
      control group (22.90 +/- 3.19) min , the survival time significantly prolonged (P 
      < 0.05, P < 0.01); compared to the same dose of acetazolamide groups (24.54 +/- 
      3.17, 22.70 +/- 3.04, 22.67 +/- 2.99, 23.93 +/- 0.96, 27.87 +/- 5.06, 30.79 +/- 
      5.12 and 35.14 +/- 6.46) min, the survival time significantly prolonged; P-8 
      groups and Acetazolamide's minimum effective dose were 6.25 and 100 mg/(kg x d), 
      the potency of P-8 is 16 times Acetazolamide. (2) In improving the endurance of 
      mice in the condition of hypoxia, the survival time of middle and high doses of 
      P-8 groups [(24.82 +/- -3.92, 28.27 +/- 5.89) min] were significantly longer than 
      those in control group [(21.96 2.51) min, P < 0.05]; compared with the 
      acetazolamide (23.11 +/- 3.71) min, the survival time of high dose of P-8 group 
      was significantly prolonged. (3) Compared with the normal control group, P-8 [(25 
      mg/(kg x d), 50 mg/(kg x d), 100 mg/(kg x d), 200 mg/(kg x d)] dose groups 
      inhibited the activity of carbonic anhydrase II (CAII) in the renal (P < 0.05, P 
      < 0.01); P-8 [100 mg/(kg x d) and 200 mg/(kg x d)] dose group significantly 
      inhibited the activity of carbonic anhydrase II (CA II) in the brain (P < 0.05). 
      CONCLUSION: P-8 treatment improved the endurance of mice in the condition of 
      hypoxia and worked better than Acetazolamide. The mechanism may be related to the 
      inhibition of carbonic anhydrase organization.
FAU - Shu, Yu-gang
AU  - Shu YG
AD  - Key Laboratory of Miltary Enviromental Medicine Institute of Health and 
      Environmental Medicine, Academy of Military Medical Sciences, Tianjin 300050, 
      China.
FAU - Zhang, Dong-xiang
AU  - Zhang DX
FAU - Xiao, Zhong-hai
AU  - Xiao ZH
FAU - Cui, Wen-yu
AU  - Cui WY
FAU - Nie, Hong-jing
AU  - Nie HJ
FAU - Zhang, Yan-kun
AU  - Zhang YK
FAU - Zhang, Yan-fang
AU  - Zhang YF
FAU - Cheng, Yue
AU  - Cheng Y
FAU - Wang, Hai
AU  - Wang H
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Ying Yong Sheng Li Xue Za Zhi
JT  - Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = 
      Chinese journal of applied physiology
JID - 9426407
RN  - 0 (Carbonic Anhydrase Inhibitors)
SB  - IM
MH  - Adaptation, Physiological/*physiology
MH  - Altitude Sickness/*prevention & control
MH  - Animals
MH  - Carbonic Anhydrase Inhibitors/*pharmacology/*therapeutic use
MH  - Hypoxia/*physiopathology
MH  - Male
MH  - Mice
EDAT- 2011/11/22 06:00
MHDA- 2013/02/22 06:00
CRDT- 2011/11/22 06:00
PHST- 2011/11/22 06:00 [entrez]
PHST- 2011/11/22 06:00 [pubmed]
PHST- 2013/02/22 06:00 [medline]
PST - ppublish
SO  - Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2011 Aug;27(3):276-9.